These strategic promotions come at a critical time as the financial sector faces various challenges, including heightened market volatility, inflationary pressures, and regulatory changes across the EU. Our team has successfully completed over 60 transactions in the past 12 months across our core sectors: Software & Fintech, Healthcare, Energy Transition & Sustainability, Industrial Tech, Business & Tech-Enabled Services, and NextGen Consumer. By bolstering our leadership team, Bryan, Garnier & Co aims to address these issues with enhanced expertise and stability and providing robust advisory services to clients, adapting to the evolving economic landscape.
Greg Revenu, Co-founder and Managing Partner of Bryan, Garnier & Co, comments “We are very pleased to be promoting our talent in line with the organic growth of our franchises, which attract many talented individuals and enable them to develop and progress rapidly in their careers in support of our clients. With these promotions, Bryan Garnier continues to grow steadily and now has more than 80 Directors, Vice Presidents & Associates, 20 Managing Directors and 16 Partners in Europe, including two new Partners – Jonathan Bohbot and Paul de Mestier – who were promoted this year.”
Olivier Garnier, Founder and Managing Partner of Bryan, Garnier & Co, adds “These promotions demonstrate our commitment to excellence and to the collective growth of Bryan Garnier, both in our sector specialisations and in our transactional expertise. This year we have been keen to promote our top performers in 4 key verticals – ECM, Healthcare, Cleantech, and Debt Capital Solutions. By investing in our teams, we are consolidating our positioning and strengthening our ability to support growth stocks over the long term in constantly changing markets.”
Grégoire Angleys
Equity Capital Markets
Grégoire Angleys is a Managing Director in the Equity Capital Markets team in the Paris office with pan-European coverage. He has over 10 years of Investment Banking experience in ECM with private placement capabilities and track-record. Before joining Bryan Garnier, he worked at Europe Offering advising US-based hedge funds investing in European healthcare and technology companies through structured products. Grégoire holds an Advanced Masters in Corporate Finance from emlyon business school and Master’s degree in Corporate and Market Finance from Grenoble IAE.
Grégoire Angleys states “I am proud to pursue my journey at Bryan, Garnier & Co, backing European companies at the forefront of innovation. Our DNA is as the trusted advisor across the lifecycle of our clients, bringing tailored solutions and thoughtful advice to founders, managers and shareholders in fast-evolving environments. Bryan, Garnier & Co’s expertise is deeply rooted in sustainability, as demonstrated with our deals with Waga Energy, Carbios and Avantium. I look forward to continuing to back the visionary teams that create technologies and solutions to address our world’s biggest challenges, notably the green transition.”
Raphael Bidaut
Investment Banking | Healthcare
Raphaël Bidaut is a Managing Director in the Healthcare practice and located in our London office with pan-European coverage. He joined Bryan Garnier in 2021 and has over 12 years of Investment Banking experience in the Healthcare sector and initially as an ECM specialist in IPOs, follow-ons and convertibles bonds for large and mid-cap companies. Raphaël graduated from Edhec Business School with a dual Master in Corporate Finance and Management.
Raphaël Bidaut states “I am honoured to be promoted after a record year from many different perspectives for the Bryan Garnier Healthcare franchise. I look forward to supporting more healthcare entrepreneurs and investors and continuing to develop our activities internationally in coordination with our 7 offices. Our Healthcare team has collectively a unique sector, M&A and equity/debt fundraising expertise. I am excited to continue leveraging them for CRO, CDMO, consumer healthcare companies and care providers.”
Paul de Froment
BG IRIS
Paul de Froment is Managing Director in Bryan Garnier’s research team IRIS and Head of the Cleantech research team. He is based in Paris and joined Bryan, Garnier & Co as an Equity Research Analyst in 2021. He previously worked at Kepler Cheuvreux for more than six years as an Equity Research Analyst focusing and small and mid caps, where he developed a solid knowledge in the fields of tech and biotech industrials. Paul holds a Master’s degree from La Sorbonne and Sciences Po Bordeaux (MSc Finance and Capital Markets).
Paul de Froment states “I strongly believe that Bryan, Garnier & Co’s unique combination of deep sector expertise and market vision will continue to position it as a key player in the Energy Transition & Sustainability landscape. Stepping into the role of Managing Director at IRIS, my focus will be on seeking innovative and valuable insights in cleantech and continuing to build a reference team in the sector. I’m committed to supporting companies as they embrace new technologies and sustainable practices to accelerate the shift to a cleaner world.”
Will Jungman
Equity Capital Markets
Will is a Director in the Debt Capital Solutions team and located in our London office with pan-European coverage. Prior to joining the firm, Will served as consultant to Bryan Garnier during which he executed several ECM and DCM deals across the Technology and Healthcare sectors. Will has a structured finance background, having spent five years working with UK property developers and operators. Prior to his career in structured finance, he worked within Deloitte Consulting’s Finance practice. Will holds an MBA from the Wharton School.
Will Jungman states “At Bryan, Garnier & Co. we pride ourselves on finding bespoke financing solutions which fit our clients’ needs. In an environment of higher interest rates and lower equity risk appetite, we have created and expanded our Debt Capital Solutions offering to provide a variety of non-dilutive or minimally-dilutive private debt products. These include landmark deals such as the structured debt financings of Abivax and Calliditas. My goal as a Director is to educate our clients on the types of private debt available to strengthen their balance sheet and fund their growth, while leading our experienced team in executing fundraisings in venture debt, growth lending, convertibles, and other private debt for European growth companies.”
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European growth investment bank that helps healthcare and technology companies become global champions. By combining extensive sector expertise with an entrepreneurial mindset, Bryan Garnier provides companies and their investors with independent growth strategic advice, and privileged access to buyers and capital in Europe, the US and Asia.
As a full-service investment bank, the firm offering includes private and public growth financing solutions, mergers and acquisitions (M&A) advisory, research insights, and institutional sales & execution. Founded in 1996, Bryan Garnier & Co is an independent partnership with around 200 employees located in major financial centres in Europe and the US.